Author

Daniel Muller

Professor, University of Toronto / Centre for Addiction and Mental Health - Cited by 17,224 - pharmacogenetics - pharmacogenomics - psychiatry - psychopharmacology - precision medicine

Biography

Dr. Daniel Mueller is Head of the Pharmacogenetics Research Clinic at the Campbell Family Mental Health Research Institute at CAMH, and Full Professor in the Department of Psychiatry at the University of Toronto. Dr. Daniel Mueller’s overarching goal is to improve drug treatment of psychiatric disorders. Pharmacogenetics holds the promise to identify gene variants that are associated with response and side-effects. Once validated, this approach will allow for precision medicine avoiding long trial-and-error strategies before the right drug for the right patient is identified.
Title
Cited by
Year
Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment
M Wada, Y Noda, Y Iwata, S Tsugawa, K Yoshida, H Tani, Y Hirano, ...Molecular Psychiatry 27 (7), 2950-2967, 2022202
31
2022
Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta‐Analysis of Prospective, Controlled Clinical Trials
LC Brown, JD Stanton, K Bharthi, AA Maruf, DJ Müller, CA BousmanClinical Pharmacology & Therapeutics 112 (6), 1303-1317, 2022202
21
2022
Gut microbiome in schizophrenia and antipsychotic-induced metabolic alterations: A scoping review
R Singh, N Stogios, E Smith, J Lee, K Maksyutynsk, E Au, DC Wright, ...Therapeutic Advances in Psychopharmacology , 204553221096525, 2022202
12
2022
Clinical impact of functional CYP2C19 and CYP2D6 gene variants on treatment with antidepressants in young people with depression: A Danish cohort study
Clinical impact of functional CYP2C1 and CYP2D6 gene variants on treatment with antidepressants in young people with depression: A Danish cohort studyLS Thiele, K Ishtiak-Ahmed, JP Thirstrup, E Agerbo, CATC Lunenburg, ...Pharmaceuticals 15 (7), 870, 2022202
9
2022
Auditory mismatch responses are differentially sensitive to changes in muscarinic acetylcholine versus dopamine receptor function
LA Weber, S Tomiello, D Schöbi, KV Wellstein, D Mueller, S Iglesias, ...Elife 11, e7435, 2022202
8
2022
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin …
CA Bousman, JM Stevenson, LB Ramsey, K Sangkuhl, JK Hicks, ...Clinical Pharmacology & Therapeutics, 2023202
7
2023
Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study
Effects of CYP2C19 and CYP2D gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 studyF Islam, VS Marshe, L Magarbeh, BN Frey, RV Milev, CN Soares, ...Translational psychiatry 12 (1), 3, 2022202
6
2022
Opioid-blunted cortisol response to stress is associated with increased negative mood and wanting of social reward
C Massaccesi, M Willeit, BB Quednow, UM Nater, C Lamm, D Müller, ...Neuropsychopharmacology 47 (10), 1798-1807, 2022202
6
2022
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis
F Islam, D Hain, D Lewis, R Law, LC Brown, JA Tanner, DJ MüllerThe pharmacogenomics journal 22 (4), 230-240, 2022202
5
2022
Trimethylamine-N-oxide is associated with cardiovascular mortality and vascular brain lesions in patients with atrial fibrillation
M Luciani, D Müller, C Vanetta, T Diteepeng, A von Eckardstein, ...Heart 109 (5), 96-404, 20220
3
2023
Gray matter volume drives the brain age gap in schizophrenia: a SHAP study
PL Ballester, JS Suh, NCW Ho, L Liang, S Hassel, SC Strother, SR Arnott, ...Schizophrenia 9 (1), , 20220
3
2023
Exploring the association of interleukin polymorphisms with aggression and internalizing behaviors in children and adolescents
JG Pouget, L Bryushkova, E Koyama, CC Zai, TM Fonseka, D Mueller, ...Brain and Behavior 1 (11), e753, 0
2
2022
Pharmacogenetics of Antipsychotic Treatment in Schizophrenia
SSM Elsheikh, DJ Müller, JG PougetPharmacogenomics in Drug Discovery and Development, 389-45, 0
2
2022
P177. Semaglutide to the Rescue: Real-World Clinical Data in Patients With Antipsychotic-Induced Weight Gain not Responding to Metformin
P77. Semaglutide to the Rescue: Real-World Clinical Data in Patients With Antipsychotic-Induced Weight Gain not Responding to MetforminF Prasad, M Agarwal, M Hahn, DJ MuellerBiological Psychiatry 9 (9), S58-S59, 2022202
1
2022
Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 report
Prediction of depression treatment outcome from multimodal data: a CAN-BIND- reportM Sajjadian, R Uher, K Ho, S Hassel, R Milev, BN Frey, F Farzan, P Blier, ...Psychological Medicine, -, 2022202
1
2022
Identification of endocannabinoid predictors of treatment outcomes in major depressive disorder: a secondary analysis of the first Canadian biomarker integration network in …
HK Kim, G Zai, DJ Müller, MI Husain, RW Lam, BN Frey, CN Soares, ...Pharmacopsychiatry 55 (06), 297-303, 2022202
1
2022
Alterations in the neural correlates of affective inhibitory control following cognitive behavioral therapy for depression: A Canadian biomarker integration network for …
P Dhami, LC Quilty, B Schwartzmann, R Uher, TA Allen, S Kloiber, ...Journal of Affective Disorders Reports 0, 0043, 2022202
1
2022
ABCB1 Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta‐Analysis Including Results from the CAN‐BIND‐1 Study
ABCB Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta‐Analysis Including Results from the CAN‐BIND‐ StudyL Magarbeh, C Hassel, M Choi, F Islam, VS Marshe, CC Zai, R Zuberi, ...Clinical Pharmacology & Therapeutics, 2023202
1
2023

Referred From: https://scholar.google.ca/citations?user=lnbto4AAAAAJ&hl=en

Cited by
Citations 17224
h-index 71
i10-index 248
Recommended Journals
Open Access Journals